Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ergomed PLC

3 Oct 2023 15:20

 
FORM 8.3
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
 
 

1

KEY INFORMATION
 
(a) Full name of discloser: MELQART ASSET MANAGEMENT (UK) LTD
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

N/A

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Ergomed PLC
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken: 2023-10-02
For an opening position disclosure, state the latest practicable date prior to the disclosure
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? No
If it is a cash offer or possible cash offer, state “N/A”
 

2

POSITIONS OF THE PERSON MAKING THE DISCLOSURE
 
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
 
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
 
Class of relevant security: 1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

(2) Cash-settled derivatives:

995,510

1.95%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

995,510

1.95%

 
All interests and all short positions should be disclosed.
 
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
(b) Rights to subscribe for new securities (including directors’ and other employee options)
 
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
 
 

3

DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a) Purchases and sales
 
Class of relevant security Purchase/sale Number of securities Price per unit (GBp)
 
 
 
(b) Cash-settled derivative transactions
 
Class of relevant security Product description Nature of dealing Number of reference securities Price per unit (GBp)
e.g. CFD e.g. opening/closing a long/short position, increasing/reducing a long/short position
1p ordinary CFD increasing a long position

8,699

1344 GBp
1p ordinary CFD increasing a long position

9,357

1344 GBp
 
(c) Stock-settled derivative transactions (including options)
 
(i) Writing, selling, purchasing or varying
 
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type Expiry date Option money paid/ received per unit
e.g. American, European etc.
 
 
(ii) Exercise
 
Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit
e.g. call option
 
 
 
(d) Other dealings (including subscribing for new securities)
 
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
 
 
 
 

4

OTHER INFORMATION
 
(a) Indemnity and other dealing arrangements
 
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None
 
 
(b) Agreements, arrangements or understandings relating to options or derivatives
 
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 
 
(c) Attachments
 
Is a Supplemental Form 8 (Open Positions) attached? No
 
 
Date of disclosure: 2023-10-03
Contact name: Ben Sharp
Telephone number: +44 (0)20 3826 4493
 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
 
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231003637910/en/

Copyright Business Wire 2023

Date   Source Headline
1st Mar 20217:00 amRNSTotal Voting Rights
25th Feb 20218:42 amRNSHolding(s) in Company
10th Feb 20217:00 amRNSNotice of Preliminary Results
26th Jan 20218:42 amEQSErgomed (ERGO): PrimeVigilance excels; CRO strengthened in US
26th Jan 20217:00 amRNSErgomed 2020 Trading Update
4th Jan 20217:00 amRNSTotal Voting Rights and Block Listing Return
15th Dec 20208:00 amEQSErgomed (ERGO): MedSource acquisition to boost US CRO business
14th Dec 20207:00 amRNSAcquisition of MedSource
24th Nov 20204:34 pmRNSHolding(s) in Company
18th Nov 20207:00 amRNSShare Capital Reduction Effective
11th Nov 20207:00 amRNSErgomed to Present at Jefferies Conference
2nd Nov 20207:00 amRNSTotal Voting Rights
21st Oct 20205:26 pmRNSHolding(s) in Company
19th Oct 202010:12 amRNSResult of General Meeting
12th Oct 20205:51 pmRNSHolding(s) in Company
1st Oct 20207:00 amRNSProposed Capital Reduction
1st Oct 20207:00 amRNSTotal Voting Rights
23rd Sep 20207:06 amRNSSecond Price Monitoring Extn
23rd Sep 20207:03 amRNSPrice Monitoring Extension
22nd Sep 20204:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:35 pmRNSPrice Monitoring Extension
22nd Sep 20207:00 amRNSInterim Results
9th Sep 20201:50 pmRNSHolding(s) in Company
1st Sep 20207:00 amRNSTotal Voting Rights
20th Aug 202011:32 amRNSHolding(s) in Company
20th Aug 20207:00 amRNSNotice of Interim Results
14th Aug 20204:19 pmRNSHoldings in Company
4th Aug 20207:00 amRNSExercise of Share Options and Total Voting Rights
3rd Aug 20207:00 amRNSTotal Voting Rights
23rd Jul 20201:02 pmRNSHoldings in Company
22nd Jul 202012:57 pmRNSHolding(s) in Company
21st Jul 20202:14 pmRNSHoldings in Company
21st Jul 20202:13 pmRNSHoldings in Company
21st Jul 20207:00 amRNSErgomed H1 2020 Trading Update
20th Jul 20205:35 pmRNSHolding(s) in Company
20th Jul 20202:08 pmRNSHolding(s) in Company
17th Jul 202012:19 pmRNSHolding(s) in Company
15th Jul 202012:03 pmRNSHolding(s) in Company
6th Jul 20204:14 pmRNSExercise of Share Options and Total Voting Rights
1st Jul 20207:00 amRNSTotal Voting Rights & Block Listing Return
29th Jun 20205:17 pmRNSHoldings in Company
10th Jun 20201:43 pmEQSEdison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
10th Jun 202010:53 amRNSResult of AGM
10th Jun 20207:00 amRNSAnnual General Meeting Statement
1st Jun 20207:00 amRNSTotal Voting Rights
28th May 20207:00 amRNSErgomed to Present at Jefferies Conference
18th May 20207:00 amRNSStrategic Partnership in Intelligent Automation
15th May 20207:00 amRNSNotice of AGM and Annual Report and Board Changes
1st May 20207:00 amRNSTotal Voting Rights
6th Apr 20207:00 amRNSErgomed Announces Second COVID-19 Clinical Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.